20:11 , Dec 7, 2018 |  BC Week In Review  |  Clinical News

Global Blood's sickle cell therapy heading for NDA

Global Blood Therapeutics Inc. (NASDAQ:GBT) said FDA agreed with a proposed regulatory path by which the company could obtain accelerated approval of voxelotor (formerly GBT-440) to treat sickle cell disease. Global Blood hopes to meet...
21:44 , Dec 3, 2018 |  BC Extra  |  Clinical News

Global Blood's sickle cell therapy heading for NDA

Global Blood Therapeutics Inc. (NASDAQ:GBT) added almost $800 million in market cap on Monday after it said FDA agreed with a proposed regulatory path by which the company could obtain accelerated approval of voxelotor (formerly...
17:33 , Nov 16, 2018 |  BC Week In Review  |  Company News

MaxCyte partners with Kite, CRISPR in nonviral gene editing deals

MaxCyte Inc. (LSE:MXCT) partnered with Kite Pharma Inc. and expanded an existing deal with CRISPR Therapeutics AG (NASDAQ:CRSP) to use its Flow Electroporation technology to engineer cells. Kite gains a non-exclusive license to use MaxCyte's...
16:37 , Sep 21, 2018 |  BC Week In Review  |  Clinical News

Roxadustat meets in Phase III for CKD patients with anemia not on dialysis

Astellas Pharma Inc. (Tokyo:4503) said roxadustat (ASP1517, FG-4592) met both primary endpoints in the Phase III ALPS trial to treat anemia in patients with chronic kidney disease (CKD) who were not receiving dialysis. On the...
19:52 , Sep 20, 2018 |  BC Extra  |  Clinical News

Roxadustat meets in Phase III for CKD patients with anemia not on dialysis

Astellas Pharma Inc. (Tokyo:4503) said roxadustat (ASP1517, FG-4592) met both primary endpoints in the Phase III ALPS trial to treat anemia in patients with chronic kidney disease who were not receiving dialysis. On the primary...
22:57 , Jul 19, 2018 |  BC Extra  |  Preclinical News

Inhibiting EIF2AK1 could help treat sickle cell disease

Researchers from Children’s Hospital of Philadelphia and University of Pennsylvania showed that inhibiting EIF2AK1 to increase fetal hemoglobin could help treat sickle cell disease. As genetic diseases such as SCD and some thalassemias affect patients...
18:52 , Jul 12, 2018 |  BC Innovations  |  Product R&D

All-in-one viruses

Having taken its lead oncolytic virus into the clinic, PsiOxus Therapeutics Ltd. is building an immuno-oncology platform that uses engineered versions of the vector to selectively target multiple genes at a time to tumor cells...
03:04 , Jun 30, 2018 |  BioCentury  |  Finance

Eyes on launches

The annual summer slowdown isn’t restricted to just the stock market this year, as the clinical catalyst calendar also appears to be on holiday in 3Q18. Buysiders are therefore turning their attention to a spate...
14:45 , Jun 29, 2018 |  BC Week In Review  |  Clinical News

Global Blood reports Phase III sickle cell data that could support accelerated approval of voxelotor

Global Blood Therapeutics Inc. (NASDAQ:GBT) reported data from Part A of the Phase III HOPE trial that it believes could support accelerated approval of voxelotor (formerly GBT440) to treat sickle cell disease. The company said...
22:24 , Jun 27, 2018 |  BC Extra  |  Clinical News

Global Blood rises on 12-week sickle cell data

Global Blood Therapeutics Inc. (NASDAQ:GBT) gained $6.05 (16%) to $44.75 Wednesday after reporting data from Part A of the Phase III HOPE study that it believes could support accelerated approval of voxelotor (formerly GBT440) to...